TCL Archive ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma. December 10, 2004
TCL Archive Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months September 27, 2013